Back to Search
PAUL SONDEL, MD PHD
MD PHD
Pediatric Hematology & Oncology Physician
NPI: 1205802360Individual
Specialties, Licenses & Credentials
Pediatric Hematology & Oncology PhysicianPrimary
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
21855(WI)
Research & Publications (20)
Preclinical and clinical development of immunocytokines.
PMID 12901228·Curr Opin Investig Drugs·2003
6-review
Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease.
PMID 12840055·J Clin Invest·2003
7-preclinical
Antibody-directed, effector cell-mediated tumor destruction.
PMID 11676280·Hematol Oncol Clin North Am·2001
6-review
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
PMID 19548853·Expert Opin Investig Drugs·2009
4-observational
Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.
PMID 19454672·J Immunol·2009
7-preclinical
Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.
PMID 19638464·Clin Cancer Res·2009
7-preclinical
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
PMID 19047298·J Clin Oncol·2009
3-trial
Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.
PMID 19201847·J Immunol·2009
7-preclinical
Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.
PMID 19346873·J Pediatr Hematol Oncol·2009
8-other
Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.
PMID 18600176·J Immunother·2008
3-trial
CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
PMID 18214476·Cancer Immunol Immunother·2008
7-preclinical
Intratumoral immunocytokine treatment results in enhanced antitumor effects.
PMID 18438664·Cancer Immunol Immunother·2008
7-preclinical
Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.
PMID 17557109·Cancer Gene Ther·2007
3-trial
Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory.
PMID 17426968·Cancer Immunol Immunother·2007
7-preclinical
Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
PMID 17163960·Immunology·2007
7-preclinical
A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients.
PMID 17255276·Clin Cancer Res·2007
3-trial
Up-regulation of Fas (CD95) expression in tumour cells in vivo.
PMID 17343612·Immunology·2007
7-preclinical
Antibody-based immunotherapy in high-risk neuroblastoma.
PMID 18081947·Expert Rev Mol Med·2007
6-review
Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.
PMID 16771862·Immunology·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 HIGHLAND AVE
MADISON, WI 53792 - Phone
- (608) 263-6420
Quick Facts
- NPI
- 1205802360
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile